CSL Behring is opening operations in Russia to fulfill certain unmet needs for biotherapies and blood plasma products. CSL Behring is also investigating opportunities to contribute to the development of the Russian pharmaceutical industry, and identify the best ways to partner with the Russian government.    According to the company, the annual usage of certain classes of these medicines in Russia is much lower than it should be, with consumption of immunoglobulins in Russia 10 to 20 times low...